Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells

Journal of Clinical Investigation

Volumn 113, Issue 7, 2004, Pages 998-1007

  Belyakov, Igor M ^a   Hammond, Scott A ^b   Ahlers, Jeffrey D ^a   Glenn, Gregory M ^b   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IOMAI Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; GENETIC CODE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INTESTINE MUCOSA; LYMPH NODE; MOUSE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; SAFETY; SKIN; SPLEEN; VACCINIA VIRUS;

EID: 1642272033     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20261     Document Type: Article

References (88)

1. Lehner, T., et al. 1996. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med. 2:767-775.
2. Belyakov, I.M., et al. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. U. S. A. 95:1709-1714.
3. Berzofsky J.A., et al. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol. Rev. 170:151-172.
4. Murphey-Corb, M., et al. 1999. Selective induction of protective MHC class 1 restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J. Immunol. 162:540-549.
5. Berzofsky, J.A., Ahlers, J.D., Belyakov, I.M. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:209-219.
6. Ahlers, J.D., Belyakov, I.M., and Berzofsky, J.A. 2003. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med. 3:285-301.
7. Schmitz, J.E., et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocyces. Science. 283:857-860.
8. Jin, X., et al. 1999. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
9. Belyakov, I.M., et al. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7:1320-1326.
10. Ahlers, J.D., Belyakov, I.M., Thomas, E.K., and Berzofsky, J.A. 2001. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 108:1677-1685.
11. Ahlers, J.D., Belyakov, I.M., Matsui, S., and Berzofsky, J.A. 2001. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13:897-908.
12. Belyakov, I.M., et al. 1998. The Importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12 J. Clin. Invest. 102:2072-2081.
13. Glenn, G.M., Scharton-Kersten, T., Vassell, R., Matyas, G.R., and Alving, C.R. 1999. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1100-1106.
14. Glenn, G.M., et al. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211-3214.
15. Berry, L.J., et al. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72:1019-1028.
16. Yu, J., et al. 2002. Transcutaneous immunization using colonization factor and heat-labile enteroroxin induces correlates of protective immunity for enteroroxigenic Escherichia coli. Infect Immun. 70:1056-1068.
17. Guerena-Burgueno, F., et al. 2002. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70:1874-1880.
18. Guebre-Xabier, M., et al. 2003. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells. J. Virol. 77:5218-5225.
19. Godefroy, S., et al. 2003. Immunization onto shaved skin with a bacterial enterotoxin adjuvant protects mice against respiratory syncytial virus (RSV). Vaccine. 21:1665-1671.
20. Seo, N., et al. 2000. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. U. S. A. 97:371-376.
21. Kahlon, R., et al. 2003. Optimization of epicutaneous immunization for the induction of CTL. Vaccine. 21:2890-2899.
22. Hammond, S.A., Walwender, D., Alving, C.R., and Glenn, G.M. 2001. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine. 19:2701-2707.
23. Baca-Estrada, M.E., et al. 2002. The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology. 107:69-76.
24. Scharton-Kersten, T., et al. 2000. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:5306-5313.
25. Glenn, G.M., et al. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403-1406.
26. Glenn, G.M., et al. 2003. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocomperence of the skin. Expert Rev. Vaccines. 2:253-267.
27. Fong, L., and Engleman, E.G. 2000. Dendritic cells in cancer immunothetapy. Annu. Rev. Immunol. 18:245-273.
28. Berzofsky, J.A., et al. 1991. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88:876-884.
29. Takahashi, H., et al. 1988. An immunodominant epitope of the HIV gp160 envelope glycoprorein recognized by class 1 MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85:3105-3109.
30. Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
31. Belyakov, I.M., et al. 1998. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. J. Virol. 72.8264-8272.
32. Belyakov, I.M., Moss, B., Strober, W., and Berzofsky, J.A. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U. S. A. 96:4512-4517.
33. Bukreyev, A., Belyakov, I.M., Berzofsky, J.A., and Murphy, B.R. 2001. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 75:12128-12140.
34. Belyakov, I.M., et al. 2001. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. Eur. J. Immunol. 31:3557-3566.
35. Klinman, D.M., Barnhart, K.M., and Conover, J. 1999. CpG motifs as immune adjuvants. Vaccine. 17:19-25.
36. Horner, A.A., et al. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167:1584-1591.
37. Earl, P.L., Koenig, S., and Moss, B. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoproteirr analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31-41.
38. Thery, C., et al. 2001. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicle. J. Immunol. 166:7309-7318.
39. McMichael, A.J., Askonas, B.A., Webster, R.G., and Laver, W.G. 1982. B-cell of T-cell immunity? Immunol. Today. 3:255-260.
40. Kaul, D., and Ogra, P.L. 1998. Mucosal responses to parenteral and mucosal vaccines. Dev. Biol. Stand. 95:141-146.
41. Moss, B. 1991. Vaccinia virus: a tool for research and vaccine development. Science. 252:1662.
42. Bukteyev, A., and Belyakov, I.M. 2002. Expression of immunomodulating molecules by recombinant viruses: can the immunogenicity of live virus be improved? Expert Rev. Vacines. 1:233-244.
43. Osterhaus, A.D., and de Vries, P. 1992. Vaccination against acute respiratory virus infections and measles in man. Immunobiology. 184:180-192.
44. Csencsits, K.L., Jutila, M.A., and Pascual, D.W. 1999. Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site. J. Immunol. 163:1382-1389.
45. Jahnsen, F.L., Farstad, I.N., Aanesen, J.P., and Brandtzaeg, P. 1998. Phenotypic distribution of T cells in human nasal mucosa differs from that in the gut. Am. J. Respir. Cell Mol. Biol. 18:392-401.
46. Xu, B., et al. 2003. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/VCA-1, and LFA-1 adhesion pathways. J. Exp. Med. 197:1255-1267.
47. Williams, M.B., and Butcher E.C. 1997. Homing of naive and memory T lymphocyte subsets to Peyer's patches, lymph nodes, and spleen. J. Immunol. 159:1746-1752.
48. Okada, T., Konishi, H., Ito, M., Nagura, H., and Asai, J. 1988. Identification of secretory immunoglobulin A in human sweat and sweat glands. J. Invest. Dermatol. 90:648-651.
49. Metze, D., Kersten, A., Jurecka, W., and Gebhart, W. 1991. Immunoglobulins coat microorganisms of skin surface: a comparative immunohistochemical and ultrastructural study of cutaneous and oral microbial symbionts. J. Invest. Dermatol. 96:439-445.
50. Beignon, A.S., Briand, J.P., Muller, S., and Partidos, C.D. 2001. Immunization onto bare skin with heatlabile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 102:344-351.
51. Shi, Z., et al. 2001. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75:11474-11482.
52. El-Ghorr, A.A., Williams, R.M., Heap, C., and Norval, M. 2000. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol. Med. Microbiol. 29:255-261.
53. Chen, D., et al. 2001. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 75:11630-11640.
54. Chen, D., Endres, R.L., Erickson, CA., Maa, Y.F., and Payne, L.G. 2002. Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine. 20:2671-2679.
55. Belyakov, I.M., et al. 2003. Shared modes of protection against poxivirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
56. Gebara, G., Magalhaes-Pinto, R., Tendler, M., Queiroz-da-Cruz, M., and Oliveira-Lima, A. 1986. Distribution of Langerhans cells in Swiss Webster mouse skin. Braz J. Med. Biol. Res. 19:131-133.
57. Bergstresser, P.R., Fletcher, C.R., and Streilein, J.W. 1980. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J. Invest. Dermatol. 74:77-80.
58. Scharton-Kersten, T., et al. 1999. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine. 17:S37-S43.
59. Marinaro, M., et al. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629.
60. Gagliardi, M.C., et al. 2000. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur. J. Immunol. 30:2394-2403.
61. Boyaka, P.N., et al. 2003. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J. Immunol. 170:454-462.
62. Belyakov, I.M., Ahlers, J.D., Clements, J.D., Strober, W., and Berzofsky, JA. 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J. Immunol. 165:6454-6462.
63. Braun, M.C., He, J., Wu, C.-Y., and Kelsall, B.L. 1999. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor B1 and B2 chain expression. J. Exp. Med. 189:541-552.
64. Gately, M.K., et al. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:495-521.
65. Schmidt, C.S., and Mescher, M.F. 2002. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 168:5521-5529.
66. Wan Y., et al. 2001. Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8+ CTL in vivo. J. Immunol. 167:5027-5033.
67. Moser, M., and Murphy, K.M. 2000. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1:199-205.
68. H2 and nonpolarized T cells. Nat. Immunol. 1:311-316.
69. Pulendran, B., Banchereau, J., Maraskovsky, E., and Maliszewski, C. 2001. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22:41-47.
70. Huang, Q., et al. 2001. The plasticity of dendritic cell responses to pathogens and their components. Science. 294:870-875.
71. Boonstra, A., et al. 2003. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197:101-109.
72. Verthelyi, D., et al. 2002. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 168:1659-1663.
73. Sparwasser, T., Vabulas, R.M., Villmow, B., Lipford, G.B., and Wagner, H. 2000. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30:3591-3597.
74. Asselin-Paturel, C., et al. 2001. Mouse type I IFN-producing cells are immature APCs with plasmacycoid morphology. Nat. Immunol. 2:1144-1150.
75. Kadowaki, N., et al. 2001. Subsets of human dendritic cell precursors express diffierent toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194:863-869.
76. Homung, V., et al. 2002. Quantitative expression of roll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168:4531-4537.
77. Guy, B., Fourage, S., Hessler, C., Sanchez, V., and Millet, M.J. 1998. Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone. Clin. Diagn. Lab Immunol. 5:732-736.
78. Enioutina, E.Y., Visic, D., and Daynes, R.A. 2000. The induction of systemic and mucosal immune responses, to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity. Vaccine. 18:2753-2767.
79. + T cells activated in cutaneous or mucosal lymphoid tissues. J. Exp. Med. 195:135-141.
80. Mora, J.R., et al. 2003. Selective imprinting of guthoming T cells by Peyer's patch dendritic cells. Nature. 42:88-93.
81. Johansson-Lindbom, B., et al. 2003. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J. Exp. Med. 198:963-969.
82. + dendritic cells but nor by Langerhans cells. Science. 301:1925-1928.
83. Kripke, M.L., Munn, C.G., Jeevan, A., Tang, J.M., and Bucana, C. 1990. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization. J. Immunol. 145:2833-2838.
84. Langenkamp, A., et al. 2003. Kinetics and expression patterns of chemokine receptors in human CD4+ T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur. J. Immunol. 33:474-482.
85. Butcher, E.C., and Picker, L.J. 1996. Lymphocyte homing and homeostasis. Science. 272:60-66.
86. Brandtzaeg, P., Farstad, I.N., and Haraldsen, G. 1999. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today. 20:267-277.
87. Kunkel, E.J., and Butcher, E.C. 2002. Chemokines and the tissue-specific migration of lymphocyres. Immunity. 16:1-4.
88. Belyakov, I.M., and Berzofsky J.A. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 20:247-253.